A detailed history of Pdt Partners, LLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 27,058 shares of EGRX stock, worth $151,524. This represents 0.01% of its overall portfolio holdings.

Number of Shares
27,058
Holding current value
$151,524
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$4.26 - $6.51 $115,267 - $176,147
27,058 New
27,058 $141,000
Q3 2023

Nov 14, 2023

BUY
$15.21 - $22.88 $300,321 - $451,765
19,745 New
19,745 $311,000
Q1 2020

May 15, 2020

SELL
$34.37 - $60.07 $1.26 Million - $2.2 Million
-36,701 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$54.32 - $64.31 $946,417 - $1.12 Million
-17,423 Reduced 32.19%
36,701 $2.21 Million
Q3 2019

Nov 14, 2019

SELL
$53.25 - $59.98 $51,972 - $58,540
-976 Reduced 1.77%
54,124 $3.06 Million
Q2 2019

Aug 14, 2019

SELL
$46.61 - $58.45 $652 - $818
-14 Reduced 0.03%
55,100 $3.07 Million
Q1 2019

May 15, 2019

BUY
$38.66 - $51.82 $417,643 - $559,811
10,803 Added 24.38%
55,114 $2.78 Million
Q4 2018

Feb 14, 2019

SELL
$36.72 - $67.73 $1.04 Million - $1.92 Million
-28,289 Reduced 38.97%
44,311 $1.79 Million
Q3 2018

Nov 14, 2018

SELL
$66.65 - $83.86 $759,210 - $955,249
-11,391 Reduced 13.56%
72,600 $5.03 Million
Q2 2018

Aug 14, 2018

BUY
$51.25 - $76.62 $12,812 - $19,155
250 Added 0.3%
83,991 $6.36 Million
Q1 2018

May 15, 2018

SELL
$52.16 - $66.86 $1.15 Million - $1.48 Million
-22,096 Reduced 20.88%
83,741 $4.41 Million
Q4 2017

Feb 14, 2018

BUY
$49.6 - $60.87 $5.25 Million - $6.44 Million
105,837
105,837 $5.65 Million

Others Institutions Holding EGRX

About EAGLE PHARMACEUTICALS, INC.


  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $72.9M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Pdt Partners, LLC Portfolio

Follow Pdt Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.